Summary
Six subjects with normal liver function (Group 1) and 7 patients with liver dysfunction (Group 2; mean ICGR15 value 30.5 (5.2) %; range 16 to 56) received a single oral dose of 1 mg temocapril, a prodrug-type ACE inhibitor, with preferentially excreted by the biliary route.
The plasma temocapril concentrations in Group 2 at 30 min and 1 h postdose were significantly higher than in Group 1, but the difference had disappeared 2 h postdosing. Although the half life of temocapril diacid in Group 2 was significantly longer than in Group 1, there was no significant difference between the two groups in AUC, Cmax or tmax. In Group 2, urinary recovery of temocapril was significantly increased, suggesting a possible delay in the bioactivation of temocapril into the diacid, but recovery of the diacid itself was not abnormal. ACE inhibitory action in Group 2 remained unchanged.
Temocapril is regarded as an ACE inhibitor the disposition and efficacy of which are little affected in patients with impaired liver function.
This is a preview of subscription content, log in via an institution to check access.
References
Gavras H, Gavras I (1988) Angiotensin converting enzyme inhibitors. Hypertension 11 [Suppl 2]: 1137–1141
Suzuki H, Kawaratani T, Shioya H, Uji Y, Saruta T, (1992) Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, Temocapril (CS-622), in humans. Biopharm Drug Dispos 13: 720. 1–10
Nakashima M, Yamamoto J, Shibata M, Uematsu T, Shinjo H, Akahori T, Shioya H, Sugiyama K, Kawahara Y (1992) Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency. Eur J Clin Pharmacol 43: 657–659
Oguchi H, Miyasaka M, Koiwai T, Tokuanga S, Hora K, Sato K, Yoshie T, Shioya H, Furuta S (1993) Pharmacokinetics of temocapril and enalapril in patients with various degree of renal insufficiency. Clin Pharmacokinet (in press)
Leevy CM, Smith F, Longueville J, Paumgartner G, Howard MM (1967) Indocyanine green clearance as a test for hepatic function. JAMA 200: 236–240
Shioya H, Shimojo M, Kawahara Y (1989) Determination of a new angiotensin-converting enzyme inhibitor (CS-622) and its active metabolite in plasma and urine by chromatography-mass spectrometry using negative ion chemical ionization. J Chromatogr 496: 129–135
Kawahara Y, Tokiwa H, Shimojo M (1985) Determination of plasma angiotensin converting enzyme activity by high-performance liquid chromatography. Ann Rep Sankyo Res Lab 37: 107–112
Yamaoka K, Nakagawa T, Uno T (1978) Statistical moment in pharmacokinetics. J Pharmacokin Biopharm 6: 547–558
Oizumi K, Koike H, Sada T, Miyamoto M, Nishino H, Matsushita Y, Jijima Y, Yanagisawa H (1988) Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor. Japan J Pharmacol 48: 349–356
Hui KK, Duchin KL, Kripalani KJ (1991) Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 49: 457–467
Gehr TWB, Sica DA, Grasela DM, Fakhry IL, Davis J, Duchin KL (1991) Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Eur J Clin Pharmacol 41: 165–169
Onishi A, Tsuboi Y, Ishizaki T (1989) Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin Pharmacol Ther 45: 657–665
Larmour I, Jackson B, Cubela R, Johnston CI (1985) Enalapril (MK-421) activation in man: importance of liver status. Br J Clin Pharmacol 19: 701–704
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Furuta, S., Kiyosawa, K., Higuchi, M. et al. Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function. Eur J Clin Pharmacol 44, 383–385 (1993). https://doi.org/10.1007/BF00316478
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00316478